Biotech Delivers 'Great' Phase 2 Data in NASH
Source: John McCamant for Streetwise Reports (12/07/2017)
read more >
Coverage Initiated on 'One of the Most Undervalued Biotech Companies in Canada'
Source: Streetwise Reports (12/06/2017)
Immuno-Oncology Candidate Yields 'Impressive' Early Clinical Results
Biotech Advances Potential 'Billion-Dollar Drug' with New Trial Launch in China
Source: Streetwise Reports (12/05/2017)
Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate
Source: Michael Sheikh for Streetwise Reports (12/04/2017)
Potential Alzheimer's Therapies Focus on Early Intervention
Source: Streetwise Reports (11/30/2017)
Analyst's 'Top Pick' Advances Vaccine Candidates
Source: Streetwise Reports (11/21/2017)
'Hot' Alzheimer's Market is Promising for Biotech with 'Novel' Drug Candidate
Source: Streetwise Reports (11/20/2017)
Maxim's Target Price on Biotech Makes It More Than a Tenbagger
Stock Price Jump Reflects Biotech's Active October
© 2017 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.